Molecular targeting of CSN5 in human hepatocellular carcinoma: A mechanism of therapeutic response

Oncogene

Volumn 30, Issue 40, 2011, Pages 4175-4184

  Lee, Y H ^a   Judge, A D ^b   Seo, D ^a   Kitade, M ^a   Gomez Quiroz L E ^a   Ishikawa, T ^a   Andersen, J B ^a   Kim, B K ^a   Marquardt, J U ^a   Raggi, C ^a   Avital, I ^a   Conner, E A ^a   MacLachlan, I ^b   Factor, V M ^a   Thorgeirsson, S S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Tekmira Pharmaceuticals Corporation   (Canada)

Author keywords

CSN5; hepatocellular carcinoma; SNALP; targeted siRNA therapeutics

Indexed keywords

BETA1 INTEGRIN; COP9 SIGNALOSOME; CULLIN; CYCLIN D1; CYCLIN DEPENDENT KINASE 6; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MESSENGER RNA; MYC PROTEIN; PROTEIN BAK; PROTEIN BCL 2; PROTEIN CSN5; PROTEIN P27; PROTEIN P53; S PHASE KINASE ASSOCIATED PROTEIN 2; SMAD2 PROTEIN; SMAD3 PROTEIN; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BIOACCUMULATION; CANCER GROWTH; CANCER STAGING; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DYSPLASIA; EARLY CANCER; ENZYME SUBSTRATE; IMMUNE RESPONSE; IN VITRO STUDY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MALE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; STEADY STATE; WESTERN BLOTTING;

CARCINOMA, HEPATOCELLULAR; CELL DIVISION; CELL LINE, TUMOR; DOWN-REGULATION; GENE KNOCKDOWN TECHNIQUES; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER NEOPLASMS; PEPTIDE HYDROLASES; RNA, SMALL INTERFERING;

EID: 80053583011     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.126     Document Type: Article

References (53)

1. Adler AS, Lin M, Horlings H, Nuyten DS, van de Vijver MJ, Chang HY. (2006). Genetic regulators of large-scale transcriptional signatures in cancer. Nat Genet 38: 421-430.
2. Adler AS, Littlepage LE, Lin M, Kawahara TL, Wong DJ, Werb Z et al. (2008). CSN5 isopeptidase activity links COP9 signalosome activation to breast cancer progression. Cancer Res 68: 506-515. (Pubitemid 351380078)
3. Arsura M, Cavin LG. (2005). Nuclear factor-kappaB and liver carcinogenesis. Cancer Lett 229: 157-169.
4. Avila MA, Berasain C, Torres L, Martin-Duce A, Corrales FJ, Yang H et al. (2000). Reduced mRNA abundance of the main enzymes involved in methionine metabolism in human liver cirrhosis and hepatocellular carcinoma. J Hepatol 33: 907-914.
5. Bae MK, Ahn MY, Jeong JW, Bae MH, Lee YM, Bae SK et al. (2002). Jab1 interacts directly with HIF-1alpha and regulates its stability. J Biol Chem 277: 9-12. (Pubitemid 34952021)
6. Bashir T, Dorrello NV, Amador V, Guardavaccaro D, Pagano M. (2004). Control of the SCF(Skp2-Cks1) ubiquitin ligase by the APC/C(Cdh1) ubiquitin ligase. Nature 428: 190-193. (Pubitemid 38374316)
7. Berasain C, Herrero JI, Garcia-Trevijano ER, Avila MA, Esteban JI, Mato JM et al. (2003). Expression of Wilms' tumor suppressor in the liver with cirrhosis: relation to hepatocyte nuclear factor 4 and hepatocellular function. Hepatology 38: 148-157. (Pubitemid 36775806)
8. Brasse D, Mathelin C, Leroux K, Chenard MP, Blaise S, Stoll I et al. (2010). Matrix metalloproteinase 11/stromelysin-3 exerts both activator and repressor functions during the hematogenous meta-static process in mice. Int J Cancer 127: 1347-1355.
9. Bruix J, Sherman M. (2005). Management of hepatocellular carcinoma. Hepatology 42: 1208-1236. (Pubitemid 43112690)
10. Bumcrot D, Manoharan M, Koteliansky V, Sah DWY. (2006). RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol 2: 711-719. (Pubitemid 44764213)
11. Chamovitz DA. (2009). Revisiting the COP9 signalosome as a transcriptional regulator. EMBO Rep 10: 352-358.
12. Claret FX, Hibi M, Dhut S, Toda T, Karin M. (1996). A new group of conserved coactivators that increase the specificity of AP-1 transcription factors. Nature 383: 453-457. (Pubitemid 26330837)
13. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. (2001). Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411: 494-498. (Pubitemid 32494397)
14. Esteva FJ, Sahin AA, Rassidakis GZ, Yuan LX, Smith TL, Yang Y et al. (2003). Jun activation domain binding protein 1 expression is associated with low p27(Kip1) levels in node-negative breast cancer. Clin Cancer Res 9: 5652-5659. (Pubitemid 37499487)
15. Feitelson MA, Sun B, Satiroglu Tufan NL, Liu J, Pan J, Lian Z et al. (2002). Genetic mechanisms of hepatocarcinogenesis. Oncogene 21: 2593-2604. (Pubitemid 34438112)
16. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. (1998). Potent and specific genetic interference by double stranded RNA in Caenorhabditis elegans. Nature 391: 806-811. (Pubitemid 28099681)
17. Fukumoto A, Ikeda N, Sho M, Tomoda K, Kanehiro H, Hisanaga M et al. (2004). Prognostic significance of localized p27Kip1 and potential role of Jab1/CSN5 in pancreatic cancer. Oncol Rep 11: 277-284.
18. Fukumoto A, Tomoda K, Yoneda-Kato N, Nakajima Y, Kato JY. (2006). Depletion of Jab1 inhibits proliferation of pancreatic cancer cell lines. FEBS Lett 580: 5836-5844. (Pubitemid 44584281)
19. Goto A, Niki T, Moriyama S, Funata N, Moriyama H, Nishimura Y et al. (2004). Immunohistochemical study of Skp2 and Jab1, two key molecules in the degradation of P27, in lung adenocarcinoma. Pathol Int 54: 675-681. (Pubitemid 39297292)
20. Hannon GJ, Rossi JJ. (2004). Unlocking the potential of the human genome with RNA interference. Nature 431: 371-378. (Pubitemid 39265678)
21. Hokaiwado N, Takeshita F, Banas A, Ochiya T. (2008). RNAi-based drug discovery and its application to therapeutics. IDrugs 11: 274-278. (Pubitemid 351481700)
22. Ito Y, Yoshida H, Matsuzuka F, Matsuura N, Nakamura Y, Nakamine H et al. (2003). Jun activation domain-binding protein 1 expression in malignant lymphoma of the thyroid: its linkage to degree of malignancy and p27 expression. Anticancer Res 23: 4121-4125. (Pubitemid 37474908)
23. Ivan D, Diwan AH, Esteva FJ, Prieto VG. (2004). Expression of cell cycle inhibitor p27(Kip1) and its inactivator Jab1 in melanocytic lesions. Mod Pathol 17: 811-818. (Pubitemid 38843364)
24. Jeffs LB, Palmer LR, Ambegia EG, Giesbrecht C, Ewanick S, MacLachlan I. (2005). A scalable, extrusion free method for efficient liposomal encapsulation of plasmid DNA. Pharm Res 22: 362-372. (Pubitemid 40558494)
25. Judge AD, Bola G, Lee AC, MacLachlan I. (2005a). Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol Ther 13: 494-504.
26. Judge AD, Robbins M, Tavakoli I, Levi J, Hu L, Fronda A et al. (2009). Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. J Clin Invest 119: 661-673.
27. Judge AD, Sood V, Shaw JR, Fang D, McClintock K, MacLachlan I. (2005b). Sequence-dependent stimulation of the mammalian innate immune response. Nat Biotechnol 23: 457-462. (Pubitemid 41724921)
28. Kaposi-Novak P, Libbrecht L, Woo HG, Lee YH, Sears NC, Coulouarn C et al. (2009). Central role of c-Myc during malignant conversion in human hepatocarcinogenesis. Cancer Res 69: 2775-2782.
29. Kashiwakura Y, Ochiai K, Watanabe M, Abarzua F, Sakaguchi M, Takaoka M et al. (2008). Down-regulation of inhibition of differentiation-1 via activation of activating transcription factor 3 and Smad regulates REIC/Dickkopf-3-induced apoptosis. Cancer Res 68: 8333-8341.
30. Kato JY, Yoneda-Kato N. (2009). Mammalian COP9 signalosome. Genes Cells 14: 1209-1225.
31. Kouvaraki MA, Korapati AL, Rassidakis GZ, Tian L, Zhang Q, Chiao P et al. (2003). Jun activation domain-binding protein 1 expression in breast cancer inversely correlates with the cell cycle inhibitor p27(Kip1). Cancer Res 63: 2977-2981. (Pubitemid 36667172)
32. Lee JS, Thorgeirsson SS. (2004). Genome-scale profiling of gene expression in hepatocellular carcinoma: classification, survival prediction, and identification of therapeutic targets. Gastroenterol-ogy 127: S51-S55. (Pubitemid 39423369)
33. Llovet JM, Bruix J. (2008). Molecular targeted therapies in hepato-cellular carcinoma. Hepatology 48: 1312-1327.
34. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF et al. (2008). Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390.
35. Mateyak MK, Obaya AJ, Sedivy JM. (1999). c-Myc regulates cyclin D-Cdk4 and-Cdk6 activity but affects cell cycle progression at multiple independent points. Mol Cell Biol 19: 4672-4683. (Pubitemid 29289505)
36. Morrissey DV, Blanchard K, Shaw L, Jensen K, Lockridge JA, Dickinson B et al. (2005a). Activity of stabilized siRNAs in a mouse model of HBV replication. Hepatology 41: 1349-1356. (Pubitemid 40770288)
37. Morrissey DV, Lockridge JA, Shaw L, Blanchard K, Jensen K, Breen W et al. (2005b). Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 23: 1002-1007. (Pubitemid 41114035)
38. Okabe H, Satoh S, Kato T, Kitahara O, Yanagawa R, Yamaoka Y et al. (2001). Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res 61: 2129-2137. (Pubitemid 32692038)
39. Pai SI, Lin YY, Macaes B, Meneshian A, Hung CF, Wu TC. (2006). Prospects of RNA interference therapy for cancer. Gene Ther 13: 464-477.
40. Panattoni M, Sanvito F, Basso V, Doglioni C, Casorati G, Montini E et al. (2008). Targeted inactivation of the COP9 signalosome impairs multiple stages of T cell development. J Exp Med 205: 465-477. (Pubitemid 351281610)
41. Parkin DM, Bray F, Ferlay J, Pisani P. (2005). Global cancer statistics. CA Cancer J Clin 55: 74-108.
42. Roberts LR, Gores GJ. (2005). Hepatocellular carcinoma: molecular pathways and new therapeutic targets. Semin Liver Dis 25: 212-225. (Pubitemid 40781073)
43. Rossi JJ. (2006). SNALPing siRNAs in vivo. Gene Ther 13: 583-584.
44. Rust C, Gores GJ. (2000). Apoptosis and liver disease. Am J Med 108: 567-574. (Pubitemid 30249035)
45. Shackleford TJ, Claret FX. (2010). JAB1/CSN5: a new player in cell cycle control and cancer. Cell Div 5: 26-39.
46. Sijen T, Fleenor J, Simmer F, Thijssen KL, Parrish S, Timmons L et al. (2001). On the role of RNA amplification in dsRNA-triggered gene silencing. Cell 107: 465-476. (Pubitemid 33152782)
47. Sui L, Dong Y, Ohno M, Watanabe Y, Sugimoto K, Tai Y et al. (2001). Jab1 expression is associated with inverse expression of p27(kip1) and poor prognosis in epithelial ovarian tumors. Clin Cancer Res 7: 4130-4135. (Pubitemid 34044637)
48. Thorgeirsson SS, Grisham JW. (2002). Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 31: 339-346. (Pubitemid 35154440)
49. Tsubari M, Taipale J, Tiihonen E, Keski-Oja J, Laiho M. (1999). Hepatocyte growth factor releases mink epithelial cells from transforming growth factor beta1-induced growth arrest by restoring Cdk6 expression and cyclin E-associated Cdk2 activity. Mol Cell Biol 19: 3654-3663. (Pubitemid 29193825)
50. Wei N, Serino G, Deng XW. (2008). The COP9 signalosome: more than a protease. Trends Biochem Sci 33: 592-600.
51. Whitehead KA, Langer R, Andersen DG. (2009). Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discovery 8: 129-138.
52. Zamore PD. (2001). RNA interference: listening to the sound of silence. Nat Struct Biol 8: 746-751.
53. Zimmermann TS, Lee AC, Akinc A, Bramlage B, Bumcrot D, Fedoruk MN et al. (2006). RNAi-mediated gene silencing in non-human primates. Nature 441: 111-114.